RxDoctor Payments Data

Sarah Guarascio

Optometrist · East Providence, RINPI 1497137582

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 42 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Oyster Point Pharma, Inc.$339
  • Alcon$288
  • Aerie Pharmaceuticals, Inc.$147
  • Sun Pharmaceutical Industries Inc.$112
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$100
  • Novartis$81
  • plus $120 from 4 others

What the payments were for

  • Food & beverage$1,186100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 65th percentile of 226 optometrist providers in Rhode Island.

See all optometrist providers in Rhode Island

Medicare billing

Part B allowed, 2024
$28,759
Medicare patients
175
Services billed
1,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine127$82,622
XiidraLifitegrast45$31,472
LumiganBimatoprost38$10,943
Cyclosporine18$5,145
Brimonidine Tartrate61$2,775
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$2,729
Latanoprost201$1,695
ErythromycinErythromycin Base77$746
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha52$663
Prednisolone Acetate15$442
Timolol Maleate27$279
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat37$274
Cephalexin12$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$37$93,566165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 226 optometrist providers in Rhode Island.

Other optometrist in East Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →